Advanz Agrees Multi-Market Omalizumab Deal With Alvotech
Gains Rights To Market Xolair Biosimilar In Europe, Canada And Australiasia
Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.
You may also be interested in...
Deal Watch: BMS Returning IL-12 Candidate To Frequent Partner Dragonfly
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Aurobindo Expects To Be In Top Three For Immunology Biosimilar – Is It Xolair?
Aurobindo is aiming for a regulatory filing in FY24/25 of its first immunology biosimilar, potentially a version of Novartis/Roche’s Xolair. Meanwhile, a pneumococcal vaccine is expected to be filed in India in the second half of FY23.
Selexis And Generium Launch Omalizumab Biosimilar In Russia
Selexis and Generium have claimed the launch of an omalizumab biosimilar in Russia, with their Genolar version of Xolair marking the third biosimilar to be launched by the pair following development with Selexis’ SUREtechnology platform.